With a hostile offer, BP don't get to see any internal data. That's why they're rare.
I'm more worried that any partnership agreement might be on bad terms due to ACW's fragile financial situation.
[INTERVIEW] Actinogen Medical reveals XanaCIDD phase 2a trials, page-14
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.2¢ |
Change
0.001(4.76%) |
Mkt cap ! $69.89M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.2¢ | 2.1¢ | $25.26K | 1.175M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2003434 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 1324428 | 9 |
View Market Depth
| Last trade - 14.32pm 25/06/2025 (20 minute delay) ? |
| ACW (ASX) Chart |